Skip to main content
Log in

A Single-Dose Pilot Trial of Intranasal Rapid-Acting Insulin in Apolipoprotein E4 Carriers with Mild–Moderate Alzheimer’s Disease

  • Short Communication
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Introduction

Intranasal (IN) insulin acutely improves verbal memory in mild cognitive impairment (MCI)/Alzheimer’s disease (AD), but its therapeutic effects may be attenuated in apolipoprotein E4 (ApoE4) carriers. Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insulin types.

Objectives

To measure the safety and efficacy of intranasally delivered RA glulisine in ApoE4 carriers with mild–moderate AD.

Methods

We performed a double-blinded, randomized, cross-over study of RA insulin glulisine in nine mild–moderate AD subjects to better understand the relationship between RA insulin, ApoE4 carrier status and memory performance.

Results

IN glulisine was well tolerated but failed to have an acute impact on cognition in ApoE4 carriers with AD. Serum insulin levels acutely dropped following treatment, but peripheral glucose levels remained unchanged.

Conclusion

Larger clinical trials of longer duration are necessary to better understand the relationships between RA insulin, ApoE4 carrier status and cognitive performance in AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29(10):1326–34.

    Article  CAS  PubMed  Google Scholar 

  2. Freiherr J, Hallschmid M, Frey WH 2nd, et al. Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27(7):505–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63–80.

    CAS  PubMed  Google Scholar 

  4. Reger MA, Watson GS, Frey WH 2nd, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451–8.

    Article  CAS  PubMed  Google Scholar 

  5. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29–38.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Schioth HB, Frey WH, Brooks SJ, Benedict C. Insulin to treat Alzheimer’s disease: just follow your nose? Expert Rev Clin Pharmacol. 2012;5(1):17–20.

    Article  PubMed  Google Scholar 

  7. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. Neuroendocrinology. 2007;86(2):136–42.

    Article  CAS  PubMed  Google Scholar 

  8. Benedict C, Hallschmid M, Schmitz K, et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology. 2007;32(1):239–43.

    Article  CAS  PubMed  Google Scholar 

  9. Jafek BW, Linschoten MR, Murrow BW. Anosmia after intranasal zinc gluconate use. Am J Rhinol. 2004;18(3):137–41.

    PubMed  Google Scholar 

  10. Davidson TM, Smith WM. The Bradford Hill criteria and zinc-induced anosmia: a causality analysis. Arch Otolaryngol Head Neck Surg. 2010;136(7):673–6.

    Article  PubMed  Google Scholar 

  11. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease. Alzheimers Dement. 2011;7(3):263–9.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Dulay MF, Gesteland RC, Shear PK, Ritchey PN, Frank RA. Assessment of the influence of cognition and cognitive processing speed on three tests of olfaction. J Clin Exp Neuropsychol. 2008;30(3):327–37.

    Article  PubMed  Google Scholar 

  13. Frank RA, Gesteland RC, Bailie J, Rybalsky K, Seiden A, Dulay MF. Characterization of the Sniff Magnitude Test. Arch Otolaryngol Head Neck Surg. 2006;132(5):532–6.

    Article  PubMed  Google Scholar 

  14. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323–31.

    CAS  PubMed Central  PubMed  Google Scholar 

  15. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349–56.

    Article  CAS  PubMed  Google Scholar 

  16. Valla J, Yaari R, Wolf AB, et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer’s susceptibility gene. J Alzheimers Dis. 2010;22(1):307–13.

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments and Conflict of Interest Disclosure

This work was supported by donations made to the HealthPartners Center for Memory and Aging and by department funds from the HealthPartners Center for Memory and Aging. The authors (M. H. Rosenbloom, T. R. Barclay, M. Pyle, B. L. Owens, A. B. Cagan, C. P. Anderson, W. H. Frey II and L. R. Hanson) have no conflicts of interest or disclosures.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael H. Rosenbloom.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 117 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosenbloom, M.H., Barclay, T.R., Pyle, M. et al. A Single-Dose Pilot Trial of Intranasal Rapid-Acting Insulin in Apolipoprotein E4 Carriers with Mild–Moderate Alzheimer’s Disease. CNS Drugs 28, 1185–1189 (2014). https://doi.org/10.1007/s40263-014-0214-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0214-y

Keywords

Navigation